There is a limited applicability of the RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria in the emergency setting because of a lack of baseline sCr measures; therefore, the additive value of NGAL testing in AKI, and NGAL and brain natriuretic peptide (BNP) testing in cardiorenal syndrome, becomes remarkable in clinical judgment accuracy as well as in patient risk stratification [12]. The gene discussed is NPPB; the disease is acute kidney injury.